Modality
mRNA
MOA
FcRni
Target
CD38
Pathway
Lipid Met
CeliacParkinson's
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
~May 2018
→ ~Aug 2019
Phase 2
Nov 2019
→ Jan 2028
Phase 2Current
NCT04743082
2,641 pts·Parkinson's
2019-11→2028-01·Terminated
2,641 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-01-101.8y awayPh3 Readout· Parkinson's
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P2/3
Termina…
Catalysts
Ph3 Readout
2028-01-10 · 1.8y away
Parkinson's
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04743082 | Phase 2/3 | Parkinson's | Terminated | 2641 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 |